Oral semaglutide launches for weight management at about $149
An FDA-approved tablet reaches the market inside the compounded price band, removing the main reason many patients took the compounded route.
Novo Nordisk introduced an oral semaglutide option for chronic weight management in January 2026, with reported cash pricing from around $149 a month at the lowest doses.
For anyone who will not inject, this is the most significant development in the category in years: an FDA-approved product at a price inside the compounded band.
The trade-offs are real. The tablet must be taken on an empty stomach with a small sip of water, with a wait before eating or taking other medicines, and absorption is more variable than the injection.
What this changes for what you pay
Most developments in this category move one of three things: the price of the branded product, which programmes are operating, or what may lawfully be compounded. Very few change the prescription requirement or the clinical review behind a prescription.
Where a development moves a figure we publish, the change is recorded with its date on our methodology page rather than edited in silently.
How to verify this yourself
Regulatory claims should be checked against the agency rather than coverage of the agency. FDA publishes warning letters searchable by company name and a drug shortage database, both free and both more current than any summary.